Novartis acquired Medicines Co., which was partnered with Alnylam. John Maraganore was a founder of Alnylam Pharmaceuticals.

The entities involved

• Alnylam Pharmaceuticals →

  biopharmaceutical company

  • AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
  • Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Sun 17:03
• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16

Related events

• Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.Sep 15
• Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Aug 28
• Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.Sep 15
• Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Sep 7
• Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.Sep 15